|Day Low/High||0.97 / 1.10|
|52 Wk Low/High||0.50 / 3.40|
Cash runway extended to January 2019
Cash runway updated into October 2018
Recent Pre-NDA Meeting Provided Guidance on Female Only NDA Filing Strategy and Post-Approval Safety Study
Call Scheduled for October 31st at 9am ET
505(b)(2) NDA on track for FDA submission in Q1 2018
Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018
Expected to be final clinical trial prior to 505(b)(2) NDA submission
Company on track for late 2017/early 2018 submission
Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.